CLOs on the Move

Tarcine

www.tarcine.com

 
Tarcine is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tarcine.com
  • 1560 Newbury Rd 161
    Thousand Oaks, CA USA 91320
  • Phone: 805.558.7037

Executives

Name Title Contact Details

Similar Companies

Artiva Biotherapeutics

Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva Biotherapeutics was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, our mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva`s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.

Opus Genetics

Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness`s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases.

eNeura Therapeutics

eNeura Therapeutics is a Medical Device company located in 240 N. Wolfe Rd., Sunnyvale, CA, United States.

Center For Innovation Inc

Center For Innovation Inc is a Butte, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AccuraGen Holdings

We have developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques in molecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.